Investors
& Media

Leading with purpose. Every day.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.



Data Provided by Refinitiv. Minimum 15 minutes delayed.

June 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
June 13, 2024

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Read more
June 12, 2024

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Read more
Sign up for Email Alerts
Email Alerts Sign-up